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CORRESPONDENCE
Specificity of BCR-ABL Antisense Oligonucleotides
To the Editor:
Recently in a very interesting publication in Blood1 it was shown 
that antisense treatment of Philadelphia-positive cell lines resulted 
in growth inhibition of chronic myelogenous leukemia (CM L) cells. 
Liposomes containing methylphosphonate oligodeoxynucleotides 
complementary to specific regions of the bcr-abl mRNA were used.
The investigators claim that growth inhibition resulted from selective 
inhibition of the expression of the p210bcr'"bl protein. A Western blot 
was screened with the 8E9 monoclonal antibody. This antibody is 
specific to the S it2 domain of the c-abl protein2 and detects the 
p21 ()lKI 111,1 as well as the pl45c'“bl. The investigators show a decrease 
of the p 2 1 ()hc,'"M expression relative to the pl45u’abl expression and 
conclude that the antisense strategy results in selective inhibition of 
expression of p210lK' ' uhl. The cell lines used were BV173 and K562. 
Both showed the same phenomenon (Figs 4 and 5 in Tari et a l1).
However, the presence of the pl45c abl in cell line BV173 is sur­
prising because this cell line lacks the normal chromosome 9 ' and, 
as a result of that, does not express the normal c-abl protein. Dikstein 
et al4 used Western blotting with the same monoclonal antibody and 
indeed demonstrated that BV173 is c-abl negative. Absence of c- 
abl mRNA in a reverse transcriptase-polymerase chain reaction assay 
was also confirmed.56
The rationale behind antisense studies is that antisense oligos are 
effective because they inhibit translation of the mRNA to which 
they are targeted. The specificity of BCR-ABL antisense oligonucle­
otides is still a controversial issue.7 We fully agree with Tari et a l1 
that protein studies are the best way to determine the effectiveness 
of an antisense approach in CML. In fact, we think that this is 
crucial.
How can Tari el al1 find that there is a selective decrease 
of p210lKI 1,1,1 relative to pl45c‘"bl in BV173 when the cell line is
pi 45 i’-uh ) negative? What does this mean for the experim ents per-
formed in K562 and the specificity of the BCR-ABL antisense oligo­
nucleotides in general? Using the same monoclonal antibody in a 
llow cytometric analysis of BVI73 cells after BCR-ABL antisense 
phosphorothioate treatment in which only viable cells were analyzed.
we observed a growth inhibitory effect but no decrease in cellular 
p 2 10hcr-ah I i  <>
W e would like these questions to be addressed. If the observation 
by Tari et a l1 holds, it may well be that BCR-ABL methylphospho- 
nates are the best alternative antisense approach in CML. This would 
be an important contribution to this field of research.
Toon F.C.M. Sinel.sers 
Ewakl J.B.M. Mensink
Division o f  Hematology 
Central Laboratory o f Hematology 
University Hospital Nijmegen 
Nijmegen, The Netherlands
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RESPONSE
Wc thank Drs Smetsers and Mensink for their very kind comments 
on our work published in the July 15, 1994 issue o f Blood.' In our
report, we studied the effect of liposomal-MPs (M Ps, methylphos-
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in the relative expression of single-copy genes has been commonly 
obtained in established cell lines maintained in long-term culture. 
They also ask what this means lor experiments performed in K562
phonate antisense bcr-abl oligonucleotides) on the growth inhibition and the specificity of the BCR-ABL antisense oligonucleotides in
of CML cell lines. Exposure of K562 and BV173 cells to L-MPs general. In our experiments, we found the antiproliferative effect of
targeted to the breakpoint junction of the bcr-abl m RNA inhibited the antisense oligonucleotides to be specific for the junctional se-
specifically the growth of the CML cells and was associated with a ' ' ' " ...........
decrease in the level of p210bcr'“bl protein. This effect was specific 
and selective and did not affect the transcript of the nonrearranged
In response to the question posed by Drs Smetsers and Men-
sink regai 
p210bcr‘"w
■ding how we find that there is a selective decrease of 
relative to p145°'nW in BV173 when the cell line is p 145c'ahl
_  i  1 1  . |
qucnce. These L-MPs are homologous to the mRNA transcript of 
bcr-abl but not the nonrearranged abl allele. The clear implication 
is that we observed a sequence specificity downregulation of the 
p 2 j()Ihi iii.i prolcjn product that led to the inhibition of cell growth.
They also remark that, using the same monoclonal antibody in a 
flow cytometric analysis of BVI73 cells after BCR-ABL antisense 
phosphorothioate treatment in which only viable cells were analyzed,
w  , r  ^  — rn  CT* -T * . ™  j -  w  w
negative, we point out that the clones cited by them were negative, they observed a growth inhibitory effect but no decrease in cellular 
whereas others have found clones that are positive.2'3 This variability p210lKT 1,1,1 levels. This is a common problem with antisense oligonu-
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cleotides. In many cases, the antiproliferative activity generated by 
antisense may be related to unexpected homologies with other tran-
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Guidelines for Management of Hemophilia A and B
To the Editor:
Furie et a l’ have provided us with an excellent summary of com­
monly accepted guidelines for management of the common hemo­
philias. Unfortunately, advances in our understanding of the molecu­
lar biology of the clotting disorders2 have not been paralleled by 
equivalent development of clinical studies defining optimum man­
agement strategies for many clinical care situations in hemophilia. 
Accordingly, even careful review of the literature does not allow 
one to formulate a comprehensive set of management guidelines that 
follows the principles of “ evidence-based”  medicine.3 Most of the 
current clinical “ guidelines”  for intensity and duration of coagula­
tion factor replacement represent consensus opinions based on the 
individual experience of experts such as Furie et al.1 Our own inter­
pretation and application of the currently available literature on treat­
ment differs in some respects from those given in this review and 
has been summarized in algorithmic form elsewhere.4
We particularly want to comment on the management of dental 
extractions in patients with hemophilia. We do not agree with the 
implication that factor replacement for 3 or more days is commonly 
needed in this situation. In hemophilia A, replacement therapy with 
a single dose for factor VIII in conjunction with tranexamic acid, 
as described by Sindet-Pederson et al,5 has not been complicated by 
delayed bleeding in our practice. In hemophilia B, only very limited 
data on combined treatment with factor IX and anti fibrinolytics have 
been presented. The report by Walsh et a I c i t e d  by Furie et a l1 
contains data on only three patients with Christmas disease that were 
treated by combined therapy (prothrombin complex concentrate with 
epsi Ion-am inocaproic aeid).
We have recently reported preliminary results with a protocol 
designed for dental extraction in hemophilia B that provides a single 
preoperative dose of purified factor IX (mononine, 60 U/kg) followed 
by oral anti fibrinolytic agents for 10 days.7 In nine patients to date 
(mean number of extractions per patient, 4; range, 1 to 17) hemosta- 
sis was excellent with no patients requiring additional replacement 
therapy. Four of the nine did have nausea with epsilon-aminocaproic 
acid, which resolved with substitution of tranexamic acid. No clinical 
thrombotic complications occurred, nor was there evidence of an 
induced hypercoaguable state as judged by molecular markers (pro­
thrombin fragment FI + 2, fibrinopeptide A, and fragment B¡3 15- 
42). Although this series represents the largest to date on dental 
extraction in hemophilia B using combined therapy, the results must 
be regarded as preliminary because of the small number of patients.
Additional well-designed clinical trials are needed for most clini­
cal management situations in hemophilia before we can confidently 
assert that our current practice guidelines represent anything more 
than expressions of personal opinion.
Benjamin Djulbegovic
George H. Goldsmith, Jr
Division o f  Medical Oncology/Hematology
Department o f  Medicine
University o f  Louisville
Louisville, KY
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We agree with the comments made by Djulbegovic and Goldsmith set of management guidelines” and that “ most of the current clinical 
that in formulating guidelines for hemophilia care, “ a careful review guidelines . . . represent consensus opinion.” 
of the literature does not allow one to formulate a comprehensive In regards to dental extractions, minimal data are available to
